Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LaunchPAD-RA study of AZD1163 in moderately-to-severely active rheumatoid arthritis
2025-522076-85-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of AZD1163 in rheumatoid arthritis (RA) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in DAS28-CRP at Week 12. Planned start Jul 2026; status: authorised.
02
Drugs
AZD1163
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-522076-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522076-85-00.